SCHEMBL22166106

SCHEMBL22166106

CCC(C)c1ccncc1C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.39
HTT P42858 1/20 0.35
TSHR P16473 1/20 0.35
LIMK1 P53667 1/20 0.34
ALDH1A1 P00352 2/20 0.33
RORC P51449 1/20 0.33
PDE2A O00408 1/20 0.33
LATS1 O95835 1/20 0.33
RPS6KA3 P51812 1/20 0.33
AAK1 Q2M2I8 2/20 0.32
SSTR4 P31391 1/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
SLC22A12 Q96S37 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
TP53 P04637 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
TRPV1 Q8NER1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24988968 0.87 LIMK1 (0.35) LIMK1ALDH1A1LATS1RPS6KA3AAK1
SCHEMBL19997547 0.86 LIMK1 (0.36) ARHTTTSHRLIMK1ALDH1A1
SCHEMBL18019706 0.82 RPS6KA3 (0.34) LIMK1ALDH1A1PDE2ALATS1RPS6KA3
SCHEMBL2737349 0.82 RPS6KA3 (0.42) LIMK1ALDH1A1LATS1RPS6KA3AAK1
SCHEMBL26272363 0.79 RPS6KA3 (0.34) LIMK1ALDH1A1LATS1RPS6KA3AAK1
SCHEMBL20940108 0.77 RPS6KA3 (0.41) HTTTSHRALDH1A1RORCLATS1
SCHEMBL10115538 0.77 RPS6KA3 (0.41) HTTTSHRALDH1A1RORCLATS1
SCHEMBL14612403 0.77 RPS6KA3 (0.41) HTTTSHRALDH1A1RORCLATS1
SCHEMBL25493980 0.75 TSHR (0.41) HTTTSHRALDH1A1RORCRPS6KA3
SCHEMBL28284268 0.75 ALDH1A1 (0.35) LIMK1ALDH1A1LATS1NPC1SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10695337-B2 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors INCYTE HOLDINGS CORPORATION (US) 2020-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10695337-B2 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors JAK1, JAK2, JAK3 AR 2490/4885HTT 2771/4885TSHR 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.